MT Newswires5d agoneutral
Boston Scientific Lowered Full-Year Guidance on Headwinds in Electrophysiology, Watchman Portfolios, RBC SaysBoston Scientific (BSX) reported Q2 revenue and EPS that beat expectations but lowered its full-year
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
531last 24h
2512last 7d
483● bullish (7d)
257● bearish (7d)
197publishers
Zacks6d agoneutral
BSX Q2 Earnings Call Highlights WATCHMAN and EP PressureBSX faces WATCHMAN and EP pressures as management cuts outlook while highlighting cost savings and new product catalysts for future growth.
Moby6d agoneutral
Boston Scientific Corporation Q2 2026 Earnings Call SummaryMoby summary of Boston Scientific Corporation's Q2 2026 earnings call
MarketBeat6d agoneutral
Boston Scientific Q2 Earnings Call HighlightsBoston Scientific (NYSE:BSX) reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competi
GuruFocus.com6d agoneutral
Boston Scientific Corp (BSX) Q2 2026 Earnings Call Highlights: Strong Growth in Interventional ...Boston Scientific Corp (BSX) reports a robust Q2 with 7% organic sales growth and a 15% increase in adjusted EPS, despite challenges in some segments.
Quartz7d agoneutral
Boston Scientific Q2 2026 earnings: profit forecast cut on Watchman slowdownThe medical device maker topped second-quarter expectations but now sees full-year adjusted EPS of $3.28 to $3.32, down from a prior range of $3.34 to $3.41
StockStory7d agobearish
Boston Scientific (NYSE:BSX) Surprises With Q2 CY2026 Sales But Quarterly Revenue Guidance Misses ExpectationsMedical device company Boston Scientific (NYSE:BSX) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 7.5% year on year to $5.44 billion. On the other hand, next quarter’s revenue guidance of $5.27 billion was less impressive, coming in 2.2% below analysts’ estimates. Its non-GAAP profit of $0.86 per share was 3.8% above analysts’ consensus estimates.
StockStory8d agoneutral
What To Expect From Boston Scientific’s (BSX) Q2 EarningsMedical device company Boston Scientific (NYSE:BSX) will be reporting earnings this Wednesday morning. Here’s what to expect.
Barchart34d agoneutral
Boston Scientific’s Quarterly Earnings Preview: What You Need to KnowBoston Scientific is gearing up for earnings day, weighing a rocky stock run against Wall Street's stubbornly optimistic outlook.
MT Newswires68d agoneutral
Boston Scientific's 2026 Guidance Intact Despite Watchman Headwind, RBC Capital Markets SaysBoston Scientific (BSX) shares fell Wednesday after Chief Executive Mike Mahoney's comments about fl
Motley Fool69d agobearish
Stock Market Today, May 27: Boston Scientific Plunges After Reiterating Underwhelming Full Year Growth GuidanceInvestors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026.
Stocktwits69d agoneutral
Why Did BSX Cut FY26 Guidance? CEO Details Three Unanticipated Factors At Bernstein ConferenceBoston Scientific's CEO stated that the company will update its three-year plan, including targets for FY27 and FY28, after the third-quarter earnings call.
Moby82d agoneutral
Elutia Inc. Q1 2026 Earnings Call SummaryMoby summary of Elutia Inc.'s Q1 2026 earnings call